Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Extrapulmonary Small Cell Neuroendocrine Carcinoma”

14 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 14 of 14 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT06816394
What this trial is testing

Tarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS)

Who this might be right for
Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma
National Taiwan University Hospital 32
Testing effectiveness (Phase 2)Active Not RecruitingNCT03896503
What this trial is testing

Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs

Who this might be right for
Extensive Stage Lung Small Cell CarcinomaExtrapulmonary Small Cell Neuroendocrine CarcinomaLimited Stage Lung Small Cell Carcinoma+3 more
National Cancer Institute (NCI) 104
Testing effectiveness (Phase 2)Looking for participantsNCT05652686
What this trial is testing

Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

Who this might be right for
Small Cell Lung Cancer (SCLC)Large Cell Neuroendocrine Cancer (LCNEC)Neuroendocrine Prostate Cancer (NEPC)+3 more
Phanes Therapeutics 203
Testing effectiveness (Phase 2)Temporarily pausedNCT05337735
What this trial is testing

A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers

Who this might be right for
Microsatellite High CancersPeritoneal MesotheliomaExtrapulmonary High Grade+5 more
M.D. Anderson Cancer Center 140
Testing effectiveness (Phase 2)Looking for participantsNCT07278479
What this trial is testing

Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

Who this might be right for
Large Cell Neuroendocrine CarcinomaLarge Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC)Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)+4 more
Molecular Partners AG 138
Testing effectiveness (Phase 2)Active Not RecruitingNCT04010357
What this trial is testing

Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC

Who this might be right for
Small-cell Lung CancerLarge Cell Neuroendocrine Carcinoma of the LungExtrapulmonary Small Cell Carcinoma
Case Comprehensive Cancer Center 14
Testing effectiveness (Phase 2)Looking for participantsNCT06464068
What this trial is testing

AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA

Who this might be right for
Extrapulmonary Small Cell Carcinoma
Gruppo Oncologico Italiano di Ricerca Clinica 66
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07328490
What this trial is testing

Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer

Who this might be right for
Extensive-Stage Small Cell Lung CancerExtrapulmonary Neuroendocrine CarcinomaSmall Cell Carcinoma
National Cancer Institute (NCI) 120
Testing effectiveness (Phase 2)Study completedNCT02487095
What this trial is testing

Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers

Who this might be right for
Carcinoma, Non-Small -Cell LungOvarian NeoplasmsSmall Cell Lung Carcinoma+3 more
National Cancer Institute (NCI) 62
Testing effectiveness (Phase 2)Looking for participantsNCT06503146
What this trial is testing

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

Who this might be right for
SarcomaSmall Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC)Mesothelioma+7 more
National Cancer Institute (NCI) 320
Early research (Phase 1)Looking for participantsNCT07080242
What this trial is testing

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

Who this might be right for
Small Cell Lung Cancer Metastatic or Locally AdvancedNeuroendocrine CancerMetastatic or Locally Advanced Neuroendocrine Prostate Cancer+5 more
SystImmune Inc. 120
Testing effectiveness (Phase 2)Ended earlyNCT05420636
What this trial is testing

Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET

Who this might be right for
Small-cell Lung CancerNeuroendocrine Carcinoma
Fox Chase Cancer Center 20
Not applicableLooking for participantsNCT02146170
What this trial is testing

Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors

Who this might be right for
Non-Small Cell Lung CancerSmall Cell Lung CancerExtrapulmonary Small Cell Cancer+2 more
National Cancer Institute (NCI) 2,000
Large-scale testing (Phase 3)Looking for participantsNCT05058651
What this trial is testing

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Who this might be right for
Advanced Extrapulmonary Neuroendocrine CarcinomaMetastatic Extrapulmonary Neuroendocrine CarcinomaRecurrent Extrapulmonary Neuroendocrine Carcinoma+1 more
National Cancer Institute (NCI)
189